Subscribe
rawpixel-com-shutterstock-com
Rawpixel.com / Shutterstock.com
29 January 2016Americas

You’re out of time: PTAB rules IPR petition is time-barred

The Patent Trial and Appeal Board (PTAB) has rejected generics company Lannett Holdings’s petition for an inter partes review (IPR) because it was filed one day too late.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.


Editor's picks

Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025

Editor's picks

Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025
Europe
EPO report reveals leading tech investors in Europe
16 January 2025
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
EOFlow ordered to pay rival $452m over insulin patch trade secrets
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.

More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.

More features

UK court upholds EU SPC precedent, rejecting MSD’s appeal
Fish & Richardson doubles down in Chicago with new office
GSK seeks damages hike in ‘skinny label’ case
UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case
Dutch court axes Biogen’s MS patent, clearing way for generics
Munck Wilson Mandala brings in first-chair patent litigator from McGuireWoods
Goodwin hires ‘impressive’ partner for NY office
Fed Circ grants Teva temporary pause in Orange Book feud